Skip to main content
Conference coverage

Marla Dubinsky, MD, on Risk Stratification in Crohn's Disease

Dr Dubinsky opened the 2024 Advances in Inflammatory Bowel Disease conference with a firm statement that virtually all patients with Crohn's disease should be treated quickly after diagnosis with approved and effective therapies—which do not include 5-ASAs— to help prevent complications and change the natural history of their disease.

 

Marla Dubinsky, MD, is a professor of Pediatrics and Medicine (Gastroenterology) at the Icahn School of Medicine and chief of Division of Pediatric Gastroenterology at Mount Sinai Kravis Children's Hospital in New York, New York.

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the AIBD Network or HMP Global, its employees, and affiliates.